Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
How frequently do you recommend ordering labs to monitor for side effects of disease modifying therapies for multiple sclerosis? Is it dependent on which DMT the patient is on?
Related Questions
How do you decide between escalation to a high efficacy DMT versus switching to a different moderate efficacy DMT in patients with poorly controlled multiple sclerosis?
How do you use optical coherence tomography in the diagnosis and management of patients with multiple sclerosis and related diseases?
What criteria do you use to decide the duration of IV steroids In patients with optic neuritis?
Do you see a current or future clinical role of neurofilament light chain in the diagnosis or workup of multiple sclerosis?
How do you distinguish between primary progressive MS versus relapsing remitting MS with superimposed relapses in a newly diagnosed patient that is naive to treatment?
What do you consider when deciding to use a high-efficacy DMT as an initial treatment in multiple sclerosis?
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
What lab levels would lead you to consider switching DMTs for patients with MS on Fingolimod?
What is the practical application of serological MS disease activity testing (offered by Octave Bio) for patients with MS?
What is your approach to dosing rituximab in patients with multiple sclerosis?
